China Pharma Holdings, Inc. (CPHI) — SEC Filings
China Pharma Holdings, Inc. (CPHI) — 22 SEC filings. Latest: 8-K (Dec 23, 2025). Includes 10 8-K, 6 10-Q, 2 DEF 14A.
View China Pharma Holdings, Inc. on SEC EDGAR
Overview
China Pharma Holdings, Inc. (CPHI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 23, 2025: On December 22, 2025, China Pharma Holdings, Inc. entered into a material definitive agreement and reported unregistered sales of equity securities. The company, formerly known as TS Electronics Inc. and Softstone Inc., is incorporated in Nevada and operates in the pharmaceutical preparations indust
Sentiment Summary
Across 22 filings, the sentiment breakdown is: 4 bearish, 18 neutral. The dominant filing sentiment for China Pharma Holdings, Inc. is neutral.
Filing Type Overview
China Pharma Holdings, Inc. (CPHI) has filed 10 8-K, 2 DEF 14A, 6 10-Q, 2 10-K, 1 SC 13G, 1 SC 13G/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (22)
Risk Profile
Risk Assessment: Of CPHI's 20 recent filings, 3 were flagged as high-risk, 7 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $2,918,271 |
| Net Income | $(1,965,421) |
| EPS | $(0.57) |
| Debt-to-Equity | 0.90 |
| Cash Position | $267,625 |
| Operating Margin | -60.17% |
| Total Assets | $15,804,793 |
| Total Debt | $7,490,796 |
Key Executives
- Zhilin Li
- Wenlong Zhan
- Yan Yang
- Kui Lai
- Jianying Cai
- Lihua Li
- Tao Liu
- Ms. Li
Industry Context
China Pharma Holdings operates within the pharmaceutical and biotechnology sector, a highly competitive and regulated industry. The sector is characterized by significant R&D investment, long product development cycles, and stringent regulatory approvals. Companies often face pressure to innovate while managing costs and navigating complex global supply chains and market access challenges.
Top Tags
10-Q (4) · pharmaceuticals (4) · Reverse Stock Split (3) · quarterly-report (3) · material-agreement (2) · material-definitive-agreement (2) · Pharmaceuticals (2) · Going Concern (2) · Net Loss (2) · Liquidity Risk (2)
Executive Compensation
From the most recent DEF 14A filing (Nov 14, 2025):
- Zhilin Li — Chairman, Chief Executive Officer: $316,000
- Zhilin Li — Chairman, Chief Executive Officer: $241,600
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Reverse Stock Split Ratio | 1:20 | Maximum proposed ratio for common stock consolidation |
| Zhilin Li's Total Annual Cash Compensation | $241,600 | For fiscal year ended December 31, 2024, including $16,000 'All Other Compensation' |
| Zhilin Li's Salary | $225,600 | For fiscal year ended December 31, 2023 |
| Shares of Common Stock Outstanding | 5,022,002 | As of Record Date November 3, 2025 |
| Shares Reserved in 2010 Long-Term Incentive Plan | 69,600 | After Amendment No.2 on December 23, 2024 |
| Yan Yang's Beneficial Ownership | 8.96% | Largest individual beneficial owner |
| Zhilin Li's Beneficial Ownership | 6.03% | Chairman's ownership percentage |
| Annual Meeting Date | December 30, 2025 | Date of the Annual Meeting of Stockholders |
| Record Date | November 3, 2025 | Date for determining stockholders entitled to vote |
| Zhilin Li's Annual Salary (PRC subsidiary) | RMB400,000 | Under new employment agreement with Helpson expiring December 31, 2029 |
| Revenue | $2,918,271 | for the nine months ended September 30, 2025, down from $3,394,934 in 2024 |
| Net Loss | $(1,965,421) | for the nine months ended September 30, 2025, an improvement from $(3,511,933) in 2024 |
| Cash and Cash Equivalents | $267,625 | as of September 30, 2025, down from $626,879 as of December 31, 2024 |
| Accumulated Deficit | $46.0 million | as of September 30, 2025, up from $44.0 million as of December 31, 2024 |
| Current Liabilities Exceeding Current Assets | $4.3 million | as of September 30, 2025, indicating a significant working capital deficit |
Forward-Looking Statements
- {"claim":"The stock price of CHINA PHARMA HOLDINGS, INC. (CPHI) may experience downward pressure due to potential dilution from the unregistered sale of equity securities.","entity":"CPHI","targetDate":"Q1 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for China Pharma Holdings, Inc. (CPHI)?
China Pharma Holdings, Inc. has 22 recent SEC filings from Jan 2024 to Dec 2025, including 10 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CPHI filings?
Across 22 filings, the sentiment breakdown is: 4 bearish, 18 neutral. The dominant sentiment is neutral.
Where can I find China Pharma Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all China Pharma Holdings, Inc. (CPHI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for China Pharma Holdings, Inc.?
Key financial highlights from China Pharma Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CPHI?
The investment thesis for CPHI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at China Pharma Holdings, Inc.?
Key executives identified across China Pharma Holdings, Inc.'s filings include Zhilin Li, Wenlong Zhan, Yan Yang, Kui Lai, Jianying Cai and 3 others.
What are the main risk factors for China Pharma Holdings, Inc. stock?
Of CPHI's 20 assessed filings, 3 were flagged high-risk, 7 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from China Pharma Holdings, Inc.?
Recent forward-looking statements from China Pharma Holdings, Inc. include guidance on {"claim":"The stock price of CHINA PHARMA HOLDINGS, INC. (CPHI) may experience downward pressure due to potential diluti.